Allovir Inc - ESG Rating & Company Profile powered by AI
Other companies in the scoring peer group for Allovir Inc are shown. This ESG score covers seventeen United Nations SDGs including: 'Clean Water & Sanitation', 'Decent Work & Economic Growth' and 'Life below Water'. The analysis of Allovir Inc is assembled by All Street Sevva using leading NLP.
Allovir Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 2.0, social score of 3.2 and governance score of 4.8.
3.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1234 | Quanterix Corp | 3.4 | Medium |
| 1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
| 1253 | Allovir Inc | 3.3 | Medium |
| 1253 | Calithera Biosciences Inc | 3.3 | Medium |
| 1253 | Cara Therapeutics Inc | 3.3 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Allovir Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Allovir Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Allovir Inc report the average age of the workforce?
Sign up for free to unlockDoes Allovir Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Allovir Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Allovir Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Allovir Inc offer flexible work?
Sign up for free to unlockDoes Allovir Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Allovir Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Allovir Inc conduct supply chain audits?
Sign up for free to unlockDoes Allovir Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Allovir Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Allovir Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Allovir Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Allovir Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Allovir Inc disclose water use targets?
Sign up for free to unlockDoes Allovir Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Allovir Inc have a product recall in the last two years?
Sign up for free to unlockDoes Allovir Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Allovir Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Allovir Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Allovir Inc disclose parental leave metrics?
Sign up for free to unlockDoes Allovir Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Allovir Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Allovir Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Allovir Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Allovir Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Allovir Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Allovir Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Allovir Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Allovir Inc disclose its waste policy?
Sign up for free to unlockDoes Allovir Inc report according to TCFD requirements?
Sign up for free to unlockDoes Allovir Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Allovir Inc disclose energy use targets?
Sign up for free to unlockDoes Allovir Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Allovir Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Allovir Inc
These potential risks are based on the size, segment and geographies of the company.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.